Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy
Aims. To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability. Methods. In this randomized, open label study, 206 patien...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2015/325851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548934462996480 |
|---|---|
| author | Jahan Ara Ainuddin Nasim Karim Sidra Zaheer Syed Sanwer Ali Anjum Ara Hasan |
| author_facet | Jahan Ara Ainuddin Nasim Karim Sidra Zaheer Syed Sanwer Ali Anjum Ara Hasan |
| author_sort | Jahan Ara Ainuddin |
| collection | DOAJ |
| description | Aims. To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability. Methods. In this randomized, open label study, 206 patients with type 2 diabetes in pregnancy who met the eligibility criteria were selected from the antenatal clinics. Insulin was added to metformin treatment when required, to maintain the target glycemic control. The patients were followed up till delivery. Maternal, and perinatal outcomes and pharmacotherapeutic characteristics were recorded on a proforma. Results. Maternal characteristics were comparable in metformin and insulin treated group. 84.9% patients in metformin group required add-on insulin therapy at mean gestational age of 26.58 ± 3.85 weeks. Less maternal weight gain (P<0.001) and pregnancy induced hypertension (P=0.029) were observed in metformin treated group. Small for date babies were more in metformin group (P<0.01). Neonatal hypoglycemia was significantly less and so was NICU stay of >24 hours in metformin group (P<0.01). Significant reduction in cost of treatment was found in metformin group. Conclusion. Metformin alone or with add-on insulin is an effective and cheap treatment option for patients with type 2 diabetes in pregnancy. This trial is registered with clinical trial registration number: Clinical trials.gov NCT01855763. |
| format | Article |
| id | doaj-art-1379b2576d04421cbaca33e127cbd90a |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-1379b2576d04421cbaca33e127cbd90a2025-02-03T06:12:39ZengWileyJournal of Diabetes Research2314-67452314-67532015-01-01201510.1155/2015/325851325851Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in PregnancyJahan Ara Ainuddin0Nasim Karim1Sidra Zaheer2Syed Sanwer Ali3Anjum Ara Hasan4Department of Obstetrics and Gynecology, Dow University of Health Sciences, Karachi 74400, PakistanDepartment of Pharmacology, Medical and Dental College, Bahria University, Karachi 75500, PakistanSchool of Public Health, Dow University of Health Sciences, Karachi 75300, PakistanDepartment of Community Health Sciences, United Medical and Dental College, Karachi 74900, PakistanDepartment of Obstetrics and Gynecology, Hamdard University Hospital, Karachi 74400, PakistanAims. To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability. Methods. In this randomized, open label study, 206 patients with type 2 diabetes in pregnancy who met the eligibility criteria were selected from the antenatal clinics. Insulin was added to metformin treatment when required, to maintain the target glycemic control. The patients were followed up till delivery. Maternal, and perinatal outcomes and pharmacotherapeutic characteristics were recorded on a proforma. Results. Maternal characteristics were comparable in metformin and insulin treated group. 84.9% patients in metformin group required add-on insulin therapy at mean gestational age of 26.58 ± 3.85 weeks. Less maternal weight gain (P<0.001) and pregnancy induced hypertension (P=0.029) were observed in metformin treated group. Small for date babies were more in metformin group (P<0.01). Neonatal hypoglycemia was significantly less and so was NICU stay of >24 hours in metformin group (P<0.01). Significant reduction in cost of treatment was found in metformin group. Conclusion. Metformin alone or with add-on insulin is an effective and cheap treatment option for patients with type 2 diabetes in pregnancy. This trial is registered with clinical trial registration number: Clinical trials.gov NCT01855763.http://dx.doi.org/10.1155/2015/325851 |
| spellingShingle | Jahan Ara Ainuddin Nasim Karim Sidra Zaheer Syed Sanwer Ali Anjum Ara Hasan Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy Journal of Diabetes Research |
| title | Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy |
| title_full | Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy |
| title_fullStr | Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy |
| title_full_unstemmed | Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy |
| title_short | Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy |
| title_sort | metformin treatment in type 2 diabetes in pregnancy an active controlled parallel group randomized open label study in patients with type 2 diabetes in pregnancy |
| url | http://dx.doi.org/10.1155/2015/325851 |
| work_keys_str_mv | AT jahanaraainuddin metformintreatmentintype2diabetesinpregnancyanactivecontrolledparallelgrouprandomizedopenlabelstudyinpatientswithtype2diabetesinpregnancy AT nasimkarim metformintreatmentintype2diabetesinpregnancyanactivecontrolledparallelgrouprandomizedopenlabelstudyinpatientswithtype2diabetesinpregnancy AT sidrazaheer metformintreatmentintype2diabetesinpregnancyanactivecontrolledparallelgrouprandomizedopenlabelstudyinpatientswithtype2diabetesinpregnancy AT syedsanwerali metformintreatmentintype2diabetesinpregnancyanactivecontrolledparallelgrouprandomizedopenlabelstudyinpatientswithtype2diabetesinpregnancy AT anjumarahasan metformintreatmentintype2diabetesinpregnancyanactivecontrolledparallelgrouprandomizedopenlabelstudyinpatientswithtype2diabetesinpregnancy |